• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Nov. 16, 2011

View Archived Issues

hESC Therapy Pioneer Geron Abandons Stem Cell R&D

After 15 years' effort, the world pioneer of human embryonic stem cell (hESC) therapy, Geron Inc., is abandoning the field and will be stopping recruitment to its ground-breaking Phase I acute spinal injury trial. Read More

Alnara Founder, Investors Return with Start-up Allena

Former executives and investors of Alnara Pharmaceuticals Inc. reunited to launch a new start-up, Allena Pharmaceuticals Inc., and disclosed Wednesday a $15 million Series A round for work on nonsystemic oral protein therapeutics for metabolic and orphan diseases. Read More

Mesoblast's Stem Cell Therapy Works in Phase II HF Trial

LONDON – Mesoblast Ltd. has revived hopes for the potential use of stem cells to treat heart disease, delivering positive results in a 60-patient Phase II trial of Revascor in congestive heart failure, and significantly for the allogeneic cell therapy, reporting the product did not provoke any adverse immune responses. Read More

Compromise on FDA Funding Ahead of Latest Stopgap Expiry

WASHINGTON – With yet another deadline looming this week, a congressional conference committee has come to terms on a "minibus" bill that includes a 2012 budget for the FDA of nearly $3.8 billion. Read More

CureVac Inks $33M Research Deal for mRNA Vaccines

CureVac GmbH entered a five-way, $33.1 million research collaboration to develop mRNA-based vaccines against undisclosed infectious disease pathogens, using its RNActive technology. Read More

Other News To Note

• Concert Pharmaceuticals Inc., of Lexington, Mass., said it inked a research collaboration with the National Institutes of Health's Therapeutics for Rare and Neglected Diseases (TRND) program to advance the firm's deuterium-modified praziquantel program as a potential treatment for schistosomiasis, a disease caused by parasitic worms. Read More

Stock Movers

Read More

Clinic Roundup

• ProFibrix BV, of Leiden, the Netherlands, said its Phase II trial with Fibrocaps in liver resection surgery resulted in a 50 percent reduction in mean time to hemostasis – the primary endpoint – compared to active control. The study enrolled 56 patients. Read More

AACR Roundup

• Mirna Therapeutics Inc., of Austin, Texas, presented preclinical data showing that mimics of five tumor suppressor miRNAs, including miR-34 and let-7, significantly inhibited the growth of liver tumors compared to controls. The five miRNA mimics were complexed with a lipid nanoparticle delivery formulation and were found to be neither toxic nor immunostimulatory. Additional preclinical work is ongoing. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe